Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Kirkham

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Rheumatology (Oxford, England)|April 14, 2017
A new era for collaboration?Jonathan C Packham, Sonya Abraham, Bruce Kirkham, et al.
Arthritis Research & Therapy|June 9, 2018
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 studyIain B McInnes, Philip J Mease, Georg Schett, et al.
Arthritis Care & Research|February 7, 2018
Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III StudyLaura C Coates, Philip J Mease, Laure Gossec, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Rheumatology (Oxford, England)|October 3, 2017
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Christopher T Ritchlin, et al.
Journal of Clinical Medicine|September 8, 2019
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAMBruno Fautrel, Bruce Kirkham, Janet E Pope, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 21, 2013
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritidesMary Chester Wasko, Elizabeth C Hsia, Bruce Kirkham, et al.
Rheumatology (Oxford, England)|August 8, 2016
Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritisBruce Kirkham, Khaldoun Chaabo, Christopher Hall, et al.
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 5, 2020
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 TrialsAlice B Gottlieb, Philip J Mease, Bruce Kirkham, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Rheumatology (Oxford, England)|April 14, 2017
A new era for collaboration?Jonathan C Packham, Sonya Abraham, Bruce Kirkham, et al.
Arthritis Research & Therapy|June 9, 2018
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 studyIain B McInnes, Philip J Mease, Georg Schett, et al.
Arthritis Care & Research|February 7, 2018
Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III StudyLaura C Coates, Philip J Mease, Laure Gossec, et al.
Lancet (London, England)|May 29, 2017
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trialPeter Nash, Bruce Kirkham, Masato Okada, et al.
Rheumatology (Oxford, England)|October 3, 2017
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Christopher T Ritchlin, et al.
Journal of Clinical Medicine|September 8, 2019
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAMBruno Fautrel, Bruce Kirkham, Janet E Pope, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 21, 2013
Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritidesMary Chester Wasko, Elizabeth C Hsia, Bruce Kirkham, et al.
Rheumatology (Oxford, England)|August 8, 2016
Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritisBruce Kirkham, Khaldoun Chaabo, Christopher Hall, et al.
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|February 5, 2020
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 TrialsAlice B Gottlieb, Philip J Mease, Bruce Kirkham, et al.
Pageof 6